Evidence map›Paper›PMID 33519206›Full record

ArticleTherapeutics and clinical risk management2021

Perioperative Glucocorticoids are Associated with Improved Recurrence-Free Survival After Pancreatic Cancer Surgery: A Retrospective Cohort Study with Propensity Score-Matching.

Yun-Xiao Zhang, Dong-Liang Mu, Ke-Min Jin, Xue-Ying Li, Dong-Xin Wang

Open access · goldAbstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Crosstalk between p38 MAPK and GR Signaling.International journal of molecular sciences · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yun-Xiao ZhangDepartment of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing, People's Republic of China.
Dong-Liang MuDepartment of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing, People's Republic of China.
Ke-Min JinKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The First Department of Hepatic, Biliary & Pancreatic Surgery, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
Xue-Ying LiDepartment of Biostatistics, Peking University First Hospital, Beijing, People's Republic of China.
Dong-Xin WangDepartment of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing, People's Republic of China.
Peking University · CNPeking University First Hospital · CNOutcomes Research Consortium · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePerioperative anesthetic management may affect long-term outcome after cancer surgery. This study investigated the effect of perioperative glucocorticoids on long-term survival in patients after radical resection for pancreatic cancer.

methodsIn this retrospective cohort study with propensity score-matching, patients who underwent radical resection for pancreatic cancer from January 2005 to December 2016 were recruited. Baseline and perioperative data including use of glucocorticoids for prevention of postoperative nausea and vomiting were collected. Patients were followed up by qualified personnel for cancer recurrence and survival. The primary outcome was the recurrence-free survival. Outcomes were compared before and after propensity matching. The association between perioperative glucocorticoid use and recurrence-free survival was analyzed with multivariable regression models.

resultsA total of 215 patients were included in the study; of these, 112 received perioperative glucocorticoids and 103 did not. Patients were followed up for a median of 74.0 months (95% confidence interval [CI] 68.3-79.7). After propensity score-matching, 64 patients remained in each group. The recurrence-free survivals were significantly longer in patients with glucocorticoids than in those without (full cohort: median 12.0 months [95% CI 6.0-28.0] vs 6.9 months [4.2-17.0], P<0.001; matched cohort: median 12.0 months [95% CI 5.8-26.3] vs 8.3 months [4.3-18.2], P=0.015). After correction for confounding factors, perioperative glucocorticoids were significantly associated with prolonged recurrence-free survivals (full cohort: HR 0.66, 95% CI 0.48-0.92, P=0.015; matched cohort: HR 0.54, 95% CI 0.35-0.84, P=0.007).

conclusionPerioperative use of low-dose glucocorticoids is associated with improved recurrence-free survival in patients following radical surgery for pancreatic cancer.

Indexed as

glucocorticoidspancreatic cancerperioperative managementsurgerysurvival

Identifiers

PMID33519206
PMCPMC7837557
OpenAlexW3123523652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.